Fibrogen announces positive topline results from phase 2 clinical trial of roxadustat for the treatment of chemotherapy induced anemia

San francisco, aug. 25, 2021 (globe newswire) -- fibrogen, inc. (nasdaq: fgen) today announced positive topline results from whitney, the company's phase 2 clinical study of roxadustat, a first-in-class oral small molecule hypoxia-inducible factor prolyl hydroxylase inhibitor (hif-phi), for the treatment of chemotherapy-induced anemia (cia).
FGEN Ratings Summary
FGEN Quant Ranking